What clinical data support the use of trabectedin in patients with myxoid liposarcoma?
From our clinical experience, patients with mixoid liposarcoma have been known for many years to benefit from therapy with trabectedin. This has been based on a number of trials performed in Europe, from our experience on a large patient access trial in the United States, as well as our experience on the phase III randomized trial of trabectedin compared to dacarbazine which resulted in a median progression-free survival improvement.
CASE: Soft-Tissue Sarcoma Case 2
Michael C is a 59-year-old social worker from Los Angeles California; his medical history is notable for obesity, COPD, and mild hypertension.
In September of 2014, Michael returns for follow up and his CT scan shows a 4 cm posterior mediastinal mass, and a 6 cm perinephric mass suspicious for metastatic disease. He initiates treatment with anthracycline and ifosfamide chemotherapy (6 cycles) for recurrent disease and shows a partial response.
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
Sarcoma Awareness Month: Impact of Molecular Testing and Individualized Treatments
July 19th 2023For Sarcoma Awareness Month, Lisa B. Ercolano, MD, and Mark Agulnik, MD, discussed the importance of understanding the genomics of sarcomas and how molecular testing can be useful in this space.
Read More